
    pending investigation of an unexpected animal toxicology finding.
  
['dementia with lewy bodies']
['htl0018318', 'placebo']

        Inclusion Criteria:

          -  Diagnosed with probable DLB according to the fourth revision of consensus diagnostic
             criteria for DLB.

          -  Clinical imaging evidence from either SPECT or MIBG cardiac scintigraphy that is
             consistent with a clinical diagnosis of DLB.

          -  Partner or caregiver able to support the patient for the duration of the clinical
             trial.

        Exclusion Criteria:

          -  Patients with a diagnosis of Parkinson disease at least 1 year prior to onset of
             dementia.

          -  Patients with the presence of severe extrapyramidal symptoms

          -  Patients with the presence of an illness/condition apart from DLB that could
             contribute to cognitive dysfunction

          -  Patients with poorly controlled hypertension despite lifestyle modifications and/or
             pharmacotherapy, who are currently on more than 2 different antihypertensive
             treatments

          -  Patients with prominent, recurrent episodes of syncope are related to orthostatic
             hypotension

          -  Patients with pulmonary disease or evidence of clinically significant moderate or
             severe pulmonary symptoms

          -  Patients who are taking a range of prohibited and restricted medication

          -  Patients who have been prescribed individualised cognitive rehabilitation, stimulation
             or training that was performed under medical supervision in the 6 months prior to the
             screening visit

          -  Patients who have any known condition(s) that may be contraindicated or interfere with
             the completion of the nuclear imaging scans.
      